65,437 trials
COPD · Chronic Bronchitis · Emphysema
Primary: Difference in Mucociliary Clearance (MCC) Between Visit 1A and Visit 2A — -1.50; -0.70 percentage difference of MCC
Constipation
Primary: Presence of Small Intestinal Bacterial Overgrowth — 8; 9 Participants — p=0.75
Abdominal Pain
Primary: Change of the Mean Pain Intensity Score Measured on a Visual Analogue Scale (VAS) Within 3 Days (and Within 1 Day) - ANCOVA — -2.48; -2.45; -2.36; -2.31 Units on a scale…
Difficult Endotracheal Intubation
Primary: Intubation Time — 66; 71 time in seconds — p=<0.05
Congenital Bleeding Disorder · Haemophilia A
Primary: Frequency of Development of FVIII Inhibitors (Greater Than or Equal to 0.6 Bethesda Units (BU)/mL) — 0; 0; 0; 0 subjects
HIV · HIV-associated Neurocognitive Disorder · Neurotoxicity
Primary: Neurometabolites Based on Magnetic Resonance Spectroscopy (MRS) — 19.38; 18.94; 27.83; 24.95 arbitrary units
Advanced or Metastatic Solid Tumors · Advanced or Metastatic Breast Cancer
Primary: Phase I: Percentage of Participants Responding to Treatment — 61.5 percent of participants with response
Suicide
Primary: Change in Treatment Engagement (Number of Participants Entering Treatment) — 4; 4 Participants
Atopic Disease (Including Allergic Conjunctivitis)
Primary: Tolerability of AC 170 0.24% Compared to Its Vehicle at Visit 1 (Day 1) — 0.9; 0.5; 0.7; 0.3 units on a scale
ATIII Deficiency
Primary: Difference in the Mean and Standard Deviation (SD) of the Calibrated Automated Thrombography (CAT) Measurements of the Control and ATIII Groups at Time 5 (on Arrival in…
Colorectal Neoplasms
Primary: Detection Rates for Adenomas — 100; 16 Adenomas
Glaucoma
Primary: Retinal Nerve Fiber Layer (RNFL) Thickness Correlation Width Global Bruch's Membrane Opening-minimum Rim Width (BMO-MRW) — 0.70 correlation coefficient
HER2-positive Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Maximum Tolerated Dose and Optimal Tolerated Dose of Pegylated Liposomal Doxorubicin Hydrochloride (Doxil) When Given in Combination With Cyclophosphamide (Phase I) — 30…
Venous Leg Ulcers
Primary: Wound Closure — 17; 23 participants
Stage IV or Recurrent Non-Small Cell Lung Cancer
Primary: Progression-Free Survival in Participants With PD-L1 Expression >= 5% — 4.21; 5.88 Months — p=0.2511